Search company, investor...
GeoVax company logo


Founded Year




About GeoVax

GeoVax (NASDAQ: GOVX) is a clinical-stage biotechnology company committed to developing safe and effective vaccines and immunotherapies against cancers and infectious diseases. The company's product pipeline includes human clinical trials for COVID-19 and head and neck cancer. Its additional research and development programs include preventive vaccines against the Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as immunotherapies for multiple solid tumors. GeoVax was founded in 1988 and is based in Smyrna, Georgia.

Headquarters Location

1900 Lake Park Drive Suite 380

Smyrna, Georgia, 30080,

United States

(678) 384-7220

Missing: GeoVax's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GeoVax's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

GeoVax Patents

GeoVax has filed 18 patents.

The 3 most popular patent topics include:

  • Vaccines
  • Immunology
  • Animal viral diseases
patents chart

Application Date

Grant Date


Related Topics




Flaviviruses, Vaccines, Animal viral diseases, Viral diseases, Hemorrhagic fevers


Application Date


Grant Date



Related Topics

Flaviviruses, Vaccines, Animal viral diseases, Viral diseases, Hemorrhagic fevers



Latest GeoVax News

GeoVax Labs posts positive data on SARS-CoV-2 vaccine in phase 2 trial

May 24, 2023

Gilnature/iStock via Getty Images GeoVax Labs (NASDAQ: GOVX ) presents updates on its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial. The presentations at Vaccines Summit Boston 2023 and CYTO 2023 meetings feature unpublished data from the open-label portion of the Phase 2 trial in hematological cancer patients. Preliminary analysis shows that CM04S1 is highly immunogenic in these patients, inducing antibody responses and T cell responses, including neutralizing antibodies. The Phase 2 clinical study will progress with a direct comparison to currently approved mRNA vaccines. CM04S1 is also being evaluated as a booster for healthy patients who previously received the Pfizer or Moderna mRNA vaccine in a separate Phase 2 trial. Data from both trials will provide insights into vaccine potential in unique patient groups and the general population. ( GOVX ) has risen 2.3% premarket. Recommended For You To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

GeoVax Frequently Asked Questions (FAQ)

  • When was GeoVax founded?

    GeoVax was founded in 1988.

  • Where is GeoVax's headquarters?

    GeoVax's headquarters is located at 1900 Lake Park Drive, Smyrna.

  • What is GeoVax's latest funding round?

    GeoVax's latest funding round is PIPE - II.

  • Who are the investors of GeoVax?

    Investors of GeoVax include H.C. Wainwright & Co., Armistice Capital, Emory University and Emtech Bio.

  • Who are GeoVax's competitors?

    Competitors of GeoVax include Humanetics, CoImmune, Profectus BioSciences, Tobira Therapeutics, Merus and 12 more.

Compare GeoVax to Competitors

Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.


Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).


Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.